199 related articles for article (PubMed ID: 16048435)
1. iNKT-cell responses to glycolipids.
Parekh VV; Wilson MT; Van Kaer L
Crit Rev Immunol; 2005; 25(3):183-213. PubMed ID: 16048435
[TBL] [Abstract][Full Text] [Related]
2. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
Wu L; Gabriel CL; Parekh VV; Van Kaer L
Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
[TBL] [Abstract][Full Text] [Related]
3. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids.
Parekh VV; Singh AK; Wilson MT; Olivares-Villagómez D; Bezbradica JS; Inazawa H; Ehara H; Sakai T; Serizawa I; Wu L; Wang CR; Joyce S; Van Kaer L
J Immunol; 2004 Sep; 173(6):3693-706. PubMed ID: 15356115
[TBL] [Abstract][Full Text] [Related]
4. The in vivo response of invariant natural killer T cells to glycolipid antigens.
Parekh VV; Lalani S; Van Kaer L
Int Rev Immunol; 2007; 26(1-2):31-48. PubMed ID: 17454263
[TBL] [Abstract][Full Text] [Related]
5. The complementarity determining region 2 of BV8S2 (V beta 8.2) contributes to antigen recognition by rat invariant NKT cell TCR.
Pyz E; Naidenko O; Miyake S; Yamamura T; Berberich I; Cardell S; Kronenberg M; Herrmann T
J Immunol; 2006 Jun; 176(12):7447-55. PubMed ID: 16751390
[TBL] [Abstract][Full Text] [Related]
6. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses.
Hung JT; Huang JR; Yu AL
J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781
[TBL] [Abstract][Full Text] [Related]
7. Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes.
Burdin N; Brossay L; Koezuka Y; Smiley ST; Grusby MJ; Gui M; Taniguchi M; Hayakawa K; Kronenberg M
J Immunol; 1998 Oct; 161(7):3271-81. PubMed ID: 9759842
[TBL] [Abstract][Full Text] [Related]
8. Invariant NK T cells: potential for immunotherapeutic targeting with glycolipid antigens.
Van Kaer L; Parekh VV; Wu L
Immunotherapy; 2011 Jan; 3(1):59-75. PubMed ID: 21174558
[TBL] [Abstract][Full Text] [Related]
9. Natural killer T cells as targets for immunotherapy of autoimmune diseases.
Van Kaer L
Immunol Cell Biol; 2004 Jun; 82(3):315-22. PubMed ID: 15186263
[TBL] [Abstract][Full Text] [Related]
10. Synthetic glycolipid ligands for human iNKT cells as potential therapeutic agents for immunotherapy.
Araki M; Miyake S; Yamamura T
Curr Med Chem; 2008; 15(23):2337-45. PubMed ID: 18855664
[TBL] [Abstract][Full Text] [Related]
11. Role of invariant natural killer T (iNKT) cells in systemic lupus erythematosus.
Godó M; Sessler T; Hamar P
Curr Med Chem; 2008; 15(18):1778-87. PubMed ID: 18691038
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapeutic potential for ceramide-based activators of iNKT cells.
Berkers CR; Ovaa H
Trends Pharmacol Sci; 2005 May; 26(5):252-7. PubMed ID: 15860372
[TBL] [Abstract][Full Text] [Related]
13. Phage display-derived recombinant antibodies with TCR-like specificity against alpha-galactosylceramide and its analogues in complex with human CD1d molecules.
Denkberg G; Stronge VS; Zahavi E; Pittoni P; Oren R; Shepherd D; Salio M; McCarthy C; Illarionov PA; van der Merwe A; Besra GS; Dellabona P; Casorati G; Cerundolo V; Reiter Y
Eur J Immunol; 2008 Mar; 38(3):829-40. PubMed ID: 18253930
[TBL] [Abstract][Full Text] [Related]
14. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
Hermans IF; Silk JD; Gileadi U; Salio M; Mathew B; Ritter G; Schmidt R; Harris AL; Old L; Cerundolo V
J Immunol; 2003 Nov; 171(10):5140-7. PubMed ID: 14607913
[TBL] [Abstract][Full Text] [Related]
15. Application of natural killer T cells in antitumor immunotherapy.
Hong C; Park SH
Crit Rev Immunol; 2007; 27(6):511-25. PubMed ID: 18197797
[TBL] [Abstract][Full Text] [Related]
16. Natural killer T cells as targets for therapeutic intervention in autoimmune diseases.
Wilson MT; Van Kaer L
Curr Pharm Des; 2003; 9(3):201-20. PubMed ID: 12570826
[TBL] [Abstract][Full Text] [Related]
17. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis.
Singh AK; Wilson MT; Hong S; Olivares-Villagómez D; Du C; Stanic AK; Joyce S; Sriram S; Koezuka Y; Van Kaer L
J Exp Med; 2001 Dec; 194(12):1801-11. PubMed ID: 11748281
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of CD1d-restricted invariant natural killer T cell-based treatment for autoimmune diseases.
Miyake S; Yamamura T
Int Rev Immunol; 2007; 26(1-2):73-94. PubMed ID: 17454265
[TBL] [Abstract][Full Text] [Related]
19. Production and characterization of monoclonal antibodies against complexes of the NKT cell ligand alpha-galactosylceramide bound to mouse CD1d.
Yu KO; Im JS; Illarionov PA; Ndonye RM; Howell AR; Besra GS; Porcelli SA
J Immunol Methods; 2007 May; 323(1):11-23. PubMed ID: 17442335
[TBL] [Abstract][Full Text] [Related]
20. Avidity of CD1d-ligand-receptor ternary complex contributes to T-helper 1 (Th1) polarization and anticancer efficacy.
Wu TN; Lin KH; Chang YJ; Huang JR; Cheng JY; Yu AL; Wong CH
Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17275-80. PubMed ID: 21987790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
